Oruka Therapeutics Announces $200 Million Private Placement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
TD Cowen Starts Oruka Therapeutics (ORKA) at Buy
September 16, 2024 5:31 AM EDTTD Cowen analyst Tyler Van Buren initiates coverage on Oruka Therapeutics (NASDAQ: ORKA) with a Buy rating.
The analyst comments "Oruka is backed by sophisticated mAb engineering and both ORKA-001 and ORKA-002 have a high PoS by targeting the same... More
Jefferies Starts Oruka Therapeutics (ORKA) at Buy
September 12, 2024 4:47 PM EDTJefferies analyst Michael Yee initiates coverage on Oruka Therapeutics (NASDAQ: ORKA) with a Buy rating and a price target of $40.00.
The analyst comments "We initiate ORKA at BUY and see high probability of success for two YTE modified "long-acting" enhanced antibodies for... More
